AAgilent Technologies

Health care · Lab Instruments · NYSE

Employees: 18,100
Headquarters: Santa Clara, CA
CEO: Padraig McDonnell
Next results: around Nov 23, 2026

RevenueFY2016–25 $6.9B+6.7% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $1.3B+1.1% Highest in 10 years 10-K FY2025 · XBRL Free cash flowFY2016–25 $1.2B−16.1% FY2024: $1.4B 10-K FY2025 · XBRL Operating marginFY2016–25 21.3%−1.6 pts 14.6% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Dec 22, 2025 against Dec 20, 2024

Area	What changed	Source
Risk factors	8 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Critical audit matters changed	New this year: Revenue Recognition for Certain Products and Services and other Revenue (“As described in Note 1 to the consolidated financial statements, the Company derives revenue primarily from the sale of analytical and diagnostics products and services. Revenue is recognized when control of the promised products or services is transferred to the customers and the performance obliga”). No longer listed: Acquisition of BIOVECTRA - Valuation of Certain Customer Relationships	10-K · XBRL
Accounting checks	10 other checks clear, 1 worth a look	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	0 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Dec 22, 2025

Paragraphs in Risk Factors that were not in the 10-K filed 2024-12-20. Quoted as filed.

Recent and dynamic government rule making and policy changes could increase our costs, affect our markets and customers and impact our results of operations. The rapid increase in new government regulations, including tariffs and proposed tariffs in the geographies and markets in which we operate, could result in significant costs and…
10-K, Item 1A

All 8 new paragraphs →

Accounting checks

latest 10-K

10 of 11 clear 1 worth a look. Checks, not verdicts.

!
Critical audit matters changedNew this year: Revenue Recognition for Certain Products and Services and other Revenue (“As described in Note 1 to the consolidated financial statements, the Company derives revenue primarily from the sale of analytical and diagnostics products and services. Revenue is recognized when control of the promised products or services is transferred to the customers and the performance obliga”). No longer listed: Acquisition of BIOVECTRA - Valuation of Certain Customer Relationships
✓
Receivables +12.3% vs revenue +6.7% (+5.6 pts)
✓
Cash from operations $1.6B vs net income $1.3B (FY ending 2025-10-31)
✓
Inventory +5.5% vs revenue +6.7% (-1.3 pts)
✓
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nothing new. The most recent filings:

Sep 8, 20268-K Director or officer change, Regulation FD disclosure 8-K items 5.02, 7.01
Sep 1, 202610-Q Quarterly report (10-Q) period ended Jul 31, 2026
Aug 26, 20268-K Quarterly results 8-K item 2.02
Jun 25, 20268-K Material agreement signed, New debt or obligation 8-K items 1.01, 2.03

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on A in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/A/export.csv") into a cell.